专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20230098327A1 SLEEP-INDUCING BEVERAGE COMPOSITION, ITS METHOD OF PRODUCTION AND THE METHOD OF USE 有权
公开(公告)号：US20230098327A1
公开(公告)日：2023-03-30
申请号：US17899150
申请日：2022-08-30
申请人： Premier Nutrition Company, LLC
发明人： Madhavi Ummadi , Nishtha Lukhmana , Venkata Sarath Pamu , Liqiang Zhao , Kimberly Ann Swisher Lutze , Emily Elizabeth Hurt
IPC分类号： A61K35/20 , A61K9/00 , A61K47/42 , A61K47/38 , A61K33/30 , A61K33/06 , A61K31/07 , A61K31/122 , A61K31/355 , A61K31/593 , A61K31/4415 , A61K31/375 , A61K31/519 , A61K31/14 , A61K47/36 , A61K47/24 , A61K38/08
摘要： Described herein is an innovative composition that improves sleep quality. This composition includes two important systems: 1) a sleep-inducing system that is being used for the first time in food and beverage products; and 2) a unique stabilizer system that provides a robust rheology and greater stability than other stabilizers. The two systems can be incorporated, individually or in combination, into food and beverage products, including but not limited to protein shakes and powders. Together, they enable this composition to aid in relaxation and optimal sleep quality, better sensory taste experiences than current market products, longer shelf life and robust stability. This disclosure also addresses a relevant need in the art for a beverage composition that promotes calmness and reduces stress by using natural ingredients, more specifically made from milk casein. In summary, the sleep-inducing RTD (ready-to-drink) and RTM (ready-to-mix) compositions described herein include a stabilizer composition that improves shelf-life stability and contributes to enhanced specific sensory attributes without any adverse effects.

2. 发明申请

US20230074237A1 METHODS FOR INCREASING GROWTH OF BENEFICIAL BACTERIA IN THE GASTROINTESTINAL TRACT 有权
公开(公告)号：US20230074237A1
公开(公告)日：2023-03-09
申请号：US17682051
申请日：2022-02-28
申请人： ABBOTT LABORATORIES
发明人： Alejandro Perez Barranco , Maria Ramirez Gonzalez , Rachael BUCK , Enrique Vazquez Hernandez
IPC分类号： A61K35/747 , A23L33/125 , A23L33/15 , A23L33/135 , A23L33/00 , A61P1/14 , A61K9/107 , A61K31/015 , A61K31/047 , A61K31/07 , A61K31/122 , A61K31/14 , A61K31/145 , A61K31/205 , A61K31/355 , A61K31/405 , A61K31/4188 , A61K31/4415 , A61K31/519 , A61K31/525 , A61K31/593 , A61K31/702 , A61K31/7072 , A61K31/7076 , A61K31/708 , A61K31/714 , A61K33/06 , A61K33/26 , A61K33/30 , A61K35/20 , A61K35/745 , A61K47/02 , A61K47/12 , A61K47/14 , A61K47/22 , A61K47/24 , A61K47/26 , A61K47/36 , A61K47/42 , A61K47/44 , A61K47/46
摘要： Disclosed are nutritional compositions including 2′-fucosyllactose (2′-FL) in combination with lutein and RRR-alpha-tocopherol. The nutritional compositions are useful for improving at least one of gut function, health, and development in an individual. In certain embodiments, the nutritional compositions can improve growth or maturation of the gut, as well as promote a healthy balance of beneficial bacteria in the gastrointestinal tract thereby treating and/or preventing formula intolerance or other gastrointestinal diseases and/or disorders resulting from suboptimal gastrointestinal flora population/balance.

3. 发明申请

US20230070870A1 Covid Nasal Spray 有权
公开(公告)号：US20230070870A1
公开(公告)日：2023-03-09
申请号：US17300640
申请日：2021-09-09
申请人： Robert V. West, III
发明人： Robert V. West, III
IPC分类号： A61K31/14 , A61K9/00
摘要： Direct instillation of a Chlorinated Solution into the Nasal passages to inactivate Covid 19 by way of Nasal spray of a Sodium Hypochlorite solution. For topical elimination of Covid 19, Solutions of 5-12.5 Parts Per Million; 5-12.5 mg. per Liter; 5-12.5% Solutions; are generally effective and considered safe by the EPA and FDA for indirect human consumption. While stronger solutions are recognized for eradication of the Coronavirus on inorganic impervious surfaces, these more dilute solutions have not previously been used for this application to the Nasal Mucosa and Nasopharynx of Humans. This new and revolutionary Process for use of Sodium Hypochlorite offers an alternative therapeutic and prophylactic modality in the war against Coronavirus (Covid-19). Sodium Hypochlorite is well known for disinfecting hard surfaces and its antimicrobial effects in higher concentrations. However, currently there are no biological products to suppress and eradicate Covid-19 in humans, besides Vaccination, Social Distancing, and Face Masks.

4. 发明授权

US11565230B2 Systems and methods for synthesizing chemical products, including active pharmaceutical ingredients 有权
公开(公告)号：US11565230B2
公开(公告)日：2023-01-31
申请号：US16988827
申请日：2020-08-10
申请人： Massachusetts Institute of Technology
发明人： Klavs F. Jensen , Timothy F. Jamison , Allan S. Myerson , Jean-Christophe M. Monbaliu , Mohsen Behnam , Shin Yee Wong , Nopphon Weeranoppanant , Eve Marie Revalor , Torsten Stelzer , Jie Chen , Andrea Adamo , David R. Snead , Ping Zhang
IPC分类号： B01J19/00 , B01J19/18 , A61K31/14 , A61K31/167
摘要： Systems and methods for synthesizing chemical products, including active pharmaceutical ingredients, are provided. Certain of the systems and methods described herein are capable of manufacturing multiple chemical products without the need to fluidically connect or disconnect unit operations when switching from one making chemical product to making another chemical product.

5. 发明申请

US20230028607A1 COMPOSITIONS AND METHODS THAT ATTENUATE COGNITIVE AGING IN INDIVIDUALS WHO DO NOT HAVE DEMENTIA 有权
公开(公告)号：US20230028607A1
公开(公告)日：2023-01-26
申请号：US17960966
申请日：2022-10-06
申请人： SOCIETE DES PRODUITS NESTLE S.A.
发明人： Claus Rieker , Julie Laure Hudry-Labbe , Jeroen Antonius Johannes Schmitt , Corina Boschat
IPC分类号： A61K31/714 , A61P25/28 , A61K31/14 , A61K31/198 , A61K31/202 , A61K31/593 , G01N33/68 , G01N33/82 , A61K31/592
摘要： A method of attenuating, treating or preventing cognitive aging in an individual who does not have dementia includes administering to the individual a therapeutically effective amount of a composition containing an omega-3 fatty acid, a nitric oxide releasing compound, Vitamin B12 and choline. The composition is administered in a daily dose that provides 0.1 to 50 times the recommended daily requirement (RDA) of Vitamin B12 per day, more preferably 0.1 to 40 times the recommended daily requirement (RDA) of Vitamin B12 per day and 0.01 to 10.0 times the recommended daily requirement (RDA) of choline. Optionally Vitamin B6 and/or Vitamin B9 can be included in the composition. The method can achieve a benefit that is one or more of decreasing brain atrophy, increasing or maintaining number of synapses, increasing amyloid-β phagocytosis, or decreasing or maintaining neuroinflammation in the non-demented individual. The method can prevent dementia in an individual at risk thereof, for example an elderly human.

6. 发明申请

US20230024844A1 STERILE AQUEOUS CHOLINE SALT COMPOSITIONS 有权
公开(公告)号：US20230024844A1
公开(公告)日：2023-01-26
申请号：US17672549
申请日：2022-02-15
申请人： Protara Therapeutics, Inc.
发明人： Dayton Reardan , Jacqueline Zummo
IPC分类号： A61K31/14 , A61J1/14 , A61K9/00
摘要： Disclosed are sterile aqueous choline salt compositions, their preparation, and methods of use. Also disclosed are methods to treat choline deficiency, intestinal failure associated liver disease (IFALD), and fatty liver disease. Additionally disclosed is a method of synthesis of choline salts.

7. 发明授权

US11547679B2 Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria and pathogenic yeast 有权
公开(公告)号：US11547679B2
公开(公告)日：2023-01-10
申请号：US16670326
申请日：2019-10-31
申请人： LUNELLA BIOTECH, INC.
发明人： Michael P. Lisanti , Federica Sotgia
IPC分类号： A61K31/55 , C07D403/04 , A61P31/00 , A61P35/00 , A61K31/137 , C07D295/135 , C07C217/74 , C07D223/04 , C07D401/04 , C07C235/46 , C07D491/107 , C07C275/24 , C07D513/04 , C07D207/06 , A61P15/16 , A61K31/14 , A61K31/155 , A61K31/66 , G16C20/50 , A61K9/00 , A61K31/40 , A61K31/436 , A61K31/519 , A61K31/5513
摘要： The present disclosure relates to inhibitors of mitochondrial function. Methods of screening compounds for mitochondrial inhibition are disclosed. Also described are methods of using mitochondrial inhibitors called mitoriboscins—mitochondrial-based therapeutic compounds having anti-cancer and antibiotic properties—to prevent or treat cancer, bacterial infections, and pathogenic yeast, as well as methods of using mitochondrial inhibitors to provide anti-aging benefits. Specific mitoriboscin compounds and groups of mitoriboscins are also disclosed.

8. 发明申请

US20230000800A1 CHOLINE BOLUS COMPOSITIONS FOR RUMINANTS 有权
公开(公告)号：US20230000800A1
公开(公告)日：2023-01-05
申请号：US17784586
申请日：2020-12-11
申请人： ALBERTA VETERINARY LABORATORIES LTD.
发明人： Merle OLSON
IPC分类号： A61K31/14 , A61K31/07 , A61K31/593 , A61K31/355 , A61P3/02 , A61K9/20 , A61K9/00 , A61K9/28
摘要： Disclosed are bolus compositions for use in the treatment or prevention of hypocalcemia and choline deficiency in ruminants. The bolus compositions may comprise rumen-protected choline, one or more calcium salts, and water.

9. 发明授权

US11491203B2 Nutraceuticals supplement composition for regulating metabolism and anti-aging 有权
公开(公告)号：US11491203B2
公开(公告)日：2022-11-08
申请号：US17203558
申请日：2021-03-16
申请人： Viva Life Science, Inc.
发明人： Thuong Cao Do , Ping Yang
IPC分类号： A61K36/9068 , A61K36/48 , A61K36/38 , A61K36/77 , A61K31/14 , A61K36/288 , A61K36/67 , A61K36/236 , A61K36/06 , A61K45/06 , A23L33/00 , A61K36/738 , A61K36/258 , A61K36/8962 , A61K9/20 , A61K9/16 , A61K9/48 , A61K36/74 , A61K36/24 , A61K36/87 , A61K36/82 , A23L33/105
摘要： Nutraceuticals Composition A (metabolic capacity enhancing compositions) comprises extraction or powder from White Kidney Bean, Green Tea, Green Coffee Bean, Garcinia Cambogia, Gymnema Sylvestre, L-Carnitine, Guarana, Ginger Root, Dandelion Root, Capsicum Cayenne, Licorice Root, Ascorbic Acid, d-Calcium Pantothenate, Pyridoxine HCl, Potassium Chloride, Magnesium Carbonate, and Chromium Yeast. Nutraceuticals Composition B (immunity capacity enhancing compositions) comprises extraction or powder from Grape Seed, Ginseng, Garlic, Rosehips, Green tea (Decaf), Astragalus, Beta Glucan Yeast, Reishi, Shitake, Maitake, Agricus blazei, Turkey Tail, Cordyceps, and Coenzyme CoQ10. The methods to make a synergistic Composition A and Composition B are formulated and are capable to provide a bioavailable dietary supplement and phytonutrients that can help modulate metabolism and enhance the human immune system. The supplementation, consumption, of these nutraceutical formulas have preventive and therapeutic roles for chronic diseases, and thus provide anti-aging effects.

10. 发明授权

US11464751B2 Use of fluoroethylnormemantine for the prevention and treatment of anxiety 有权
公开(公告)号：US11464751B2
公开(公告)日：2022-10-11
申请号：US16772582
申请日：2018-12-17
申请人： REST THERAPEUTICS
发明人： Gilles Rubinstenn
IPC分类号： A61K31/13 , A61P25/22 , A61K31/14 , A61K45/06
摘要： The present invention relates to fluoroethylnormemantine or one of the salts thereof for the treatment of anxiety and, more particularly, post-traumatic stress conditions, either alone or in combination with chemical antidepressant treatments or cognitive and behavioral techniques.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式